Relying on Caprion’s CellCarta proteomics technology to develop panels of protein diabetes biomarkers, this project will improve early diagnosis and monitor disease progression, as well as, evaluate therapeutic response.
A unique panel of clinically validated pancreatic ß-cell biomarkers readily detected in blood were discovered which serve to rapidly identify early pre-diabetic subjects and follow their disease progression. Treating this group early has the best chance to impact subjects with this long-term
This ambitious project, conducted by Dr. Paramithiotis, has 2 specific objectives: i) to identify and validate protein biomarker candidates associated with the mass and the functional state of pancreatic beta-cells, which play a critical role in the development of type 2 diabetes, and ii) to identify and complete early stage evaluation of protein biomarker candidates that can be used to monitor type 2 diabetes treatment efficacy. Using Caprion’s CellCarta proteomic platform, the team conducted an extensive analysis of pancreatic proteins secreted normally and under disease conditions from humans and several animal models of diabetes. Using three different experimental models (mouse and rat beta cell lines and human pancreatic islets), the team identified a promising dataset of candidate biomarkers for both beta cell mass and function. The proteins identified were grouped as a network and the main pathways found are derived from i) mechanisms of secretion, ii) lipid metabolism, and iii) carbohydrate metabolism. “The set of biomarkers identified during the discovery phase is impressive. All the assays we are currently developing could become the basis of diagnostic tests to monitor pre-diabetes, enable targeted therapies, and monitor beta-cell status in transplant patients,” declares Dr. Eustache Paramithiotis. The biomarkers are currently being validated in humans as well as diabetes animal models.
Impact on the drug discovery process
For more information